RENOVARO

LIVE LONGER

AI Driven Nx Generation Precision Oncology

NASDAQ: RENB

January 2025

Forward Looking Statements

Statements in this presentation that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date hereof.

Renovaro aims to accelerate precision and personalized medicine by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and discovery of new therapies.

RENOVARO
LIVE LONGER

Inflection Point in Medicine

Nvidia's latest chip sets make it possible to run the **trillions of calculations** needed for early cancer detection & personalized cancer vaccines.

New Leadership

Team of technology, biotechnology and pharmaceutical experts driving new focus and strategy.

Innovative Technology

Developing AI Cube platform, a cost-effective next generation of highly accurate diagnostics using a multi-omics, multi-modal AI-powered diagnostic engine for applying liquid biopsies.

Product Pipeline

Preclinical Dendritic Cell Cancer Vaccine (DCCV) and first product in lung cancer monitoring with development pipeline that creates value streams from broad range of products and services.

NASDAQ: RENB	
Closing Price (01/06/25)	$1.00
52 Week Range	$0.40 - $5.25
Market Cap	$158.7M
Shares Outstanding[1]	158.7M
Float	77.7M
Headquarters	Los Angeles

1. As of November 11, 2024

Renovaro's *Renewal* Long-Term Goal

To deliver a point of care solution for multi-cancer early detection from a simple blood draw and clinical decision support for choosing best therapy for patients.



When cancer is detected to deliver a personalized cancer vaccine.

We Are at an Inflection Point in Medicine

*The Potential of AI + Nvidia's latest chips make it possible to run the **trillions of calculations analyze vast data sets***

With Nebul's* Nvidia's High Computing Power and the Lower Price of Processing We Are:

Using our AI Cube platform to create diagnostics for early-stage cancer and identifying new biomarkers for our Cancer Vaccine Platform



Extracting Data From Liquid Biopsy's and Tissue Repository to power several business verticals

- Early cancer detection
- Selection of the optimal therapy for the patient
- Provide cancer monitoring



Our Personalized Dendritic Cell Cancer Vaccine Platform (DCCV) supercharges our immune system to target each person's cancer

*Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

Near Term Key Developments

RENOVARO
LIVE LONGER



Data Analytics

Advanced Genomics

RENOVARO
LIVE LONGER

Agnostic Platform

Differential diagnostic report

10.000 unique proprietary biomarkers

13 tumors validated in-silico

150,000 Live Tumor Samples

With Drug Response Data

One routinely applicable assay

Multi-signal & Multi-Omics

From a single vial of blood

Capturing Oxford Nanopore technology

Expanding our Bio-Bank, Adding AI Powered Multi-omic Drug Discovery Program and Clinical Decision Support Business Through the Acquisition Of Predictive Oncology, Inc. (NASDAQ: POAI) in All Stock Transaction

RENOVARO
LIVE LONGER

Validated proprietary platform proven to predict tumor-drug response with ***92% accuracy***

Biobank

- 150k frozen / live tumor samples
- 20 years of drug response data
- 40k FFPE tissue blocks
- 200k pathology slides & digital library

Core Capabilities

- CLIA Laboratory (NYSDOH, CA & PA)
- Software Development
- Pathology & Computational Biology

Predictive Oncology®

Value Proposition & Differentiation

- Biomarker Discovery and Development
- Increase Probability of Technical Success (PTS) for New and Repurposed Drugs
- Proteomics and Signature Identification
- Patient Stratification and Clinical Trial Optimization
- Clinical Decision Support Tools

Tumor Type Estimates / Overview	Sample Count	Histopathology	Banked Vials	Historical Drug Response	Targeted Mutations	IHC	FFPE Blocks Slides	Digitized Slides
Gastrointestinal	6,000	100%	100%	100%	5%	5%	5%	1%
Brain	150	100%	100%	91%				
Breast	2,300	100%	100%	100%	5%	3%	3%	3%
Head & Neck	200	100%	100%	100%	1%		1%	
GU	500	100%	100%	100%	0-3%	2%	3%	
Liver	150	100%	100%	100%	0-3%	3%	3%	1%
Lung	6,100	100%	100%	100%	1-6%	4%	6%	3%
Melanoma	300	100%	100%	100%	2%	2%	2%	
Mesothelioma	200	100%	100%	100%	2%	3%	3%	1%
Ovary	30,000	100%	100%	100%	9-13%	9-13%	2%	1%
Pancreas	600	100%	100%	100%	5%	5%	5%	1%
Sarcoma	700	100%	100%	100%	5%	5%	5%	1%
Uterine	20,000	100%	100%	100%	15-20%	20%	20%	3%

Core Capabilities

RENOVARO
LIVE LONGER

- **Cell culture – 2D and 3D**
  - Multiple assays
  - HTS with ML
  - Organoids and Spheroids
- **Biobank preservation and expansion**
  - Frozen cells, FFPE, slides

- **Bioinformatics/Comp Bio**
- **Software Development**
  - NGS Pipeline Development
  - Tissue Imaging Pattern & Feature Extraction
  - High-Throughput Drug Sensitivity Analysis
  - Machine Learning
  - Biomarker Discovery

Unique Set of Assets, Scientific Qualifications and Competencies

- **Histology and IHC**
- **DNA/RNA extraction**
- **qPCR**
- **NGS**
- **Histopathology slide digitization**
- **Cell Painting/HCI**

- **Licensure**
  - Board-certified Pathologist
  - CLIA / PADOH/NYSDOH/CADOH
    - Rhode Island, Maryland

Accelerating Drug Discovery while Mitigating Risk

RENOVARO
LIVE LONGER

As long as **5** years

Traditional Pre-clinical drug discovery process

Molecules / targets → Screening → Hit to Lead → Lead Optimization → Candidate selection

As little as **3** months

PEDAL pre-clinical drug discovery methodology

Initial data → Drug and tissue features (biobank) → Active learnings (CORE) → Tumor assays (wet lab) → "Go" Or "No Go"

Increased chance of clinical success with intelligence gathered during the pre-clinical phase

Multiple Approaches to Increase Probability of Technical Success (PTS)

RENOVARO
LIVE LONGER



Hundreds of compounds with 1-4 tumor types to select best drug/tumor type combination

Top compound in combination with SoC for drug combination selection

Tens of compounds to identify strongest candidate for development

Evaluation of failed compounds in new tumor types to repurpose strong drugs

Biomarker discovery and development

Pipeline Development and Replenishment

Global Pharma Contracts Validate Our Model

RENOVARO
LIVE LONGER

Typical deals average $25M upfront; $500M - $2B in milestones and royalties

AZN / Quell Therapeutics Ltd.

June 2023
$85M upfront, inc. equity investment
$2 billion in potential milestones
Sales royalties

Pfizer / CytoReason

September 2022
$20M upfront
$90M in potential milestones
5 years

Sanofi / Atomwise

August 2022
$20M upfront
$1B in potential milestones
5 targets

Lilly / Verge

June 2021
$25M upfront
$694 in potential milestones
4 targets
3 years

Lilly / Schrodinger

June 2019
$425M in potential milestones
1 target

Lilly / Atomwise

June 2019
$1M discovery milestone
$550M in potential development and commercialization milestones
10 targets

Latest - Sept 2023: Verge Genomics signs four-year, $42 million upfront, $840M in milestones plus royalties deal plus equity with Alexion/AZN to find new targets for rare neurodegenerative diseases.

Market Positioning

Addressing a > $150B market



Product 1: Lung Cancer Monitoring

Improve patient survival by dynamic and accurate treatment monitoring

RENOVARO
LIVE LONGER

Problem

Of all curatively treated patients 60% will relapse.

Current imaging modalities cope with low performance in monitoring the tumor's progression/regression resulting in under- and over- treatment

Solution

Minimally invasive blood test that accurately measures real-time tumor burden to guide personalized treatment plans with effective go/no-go recommendations

Unique Features

AI-driven, multi-omic, cost-effective (~$1,500/test), highly accurate (> 0.95), fast turnaround time, scalable

Market

5.7M lung cancer cases are treated or monitored globally; Total addressable market $17.1B based on average 3 tests per patient

Preliminary Results

Our multi-omics show an accuracy of 0.84 for multi-omics vs 0.70 using single omics trained on only 50 lung cancer patients

Product 2: Cancer of Unknown Primary

Enabling tailored treatments to enhance patient outcomes

RENOVARO
LIVE LONGER

Problem

Cancer of Unknown Primary (CUP) patients, diagnosed with metastatic disease but an unknown primary tumor, face a median survival of just 3-6 months, presenting a critical unmet need in oncology

Solution

A cutting-edge, minimally invasive blood test that detects the primary tumor through molecular signatures, enabling personalized treatment and significantly improving patient survival

Unique Features

AI-driven, multi-omic, cost-effective (~$1,000/test), highly accurate (> 0.95), fast turnaround time, scalable

Market

400,000 Cancer of Unknow Primary patients globally; Total addressable market $400M based on a single test per patient

Preliminary Results

Single omics train& test-models achieve an accuracy up to 0.95, **thereby outperforming clinical standards**

Product 3: ChemoFx

Clinical decision support for choosing best therapy for patient

Problem

The oncologist doesn't know which of the potential chemotherapies or drugs will work best for a patient

Solution

ChemoFx analyzes chemotherapy-drug effectiveness on a patient's live cancer cells to help identify the drug regimen with the best potential to fight the cancer.

Unique Features

Live-cell samples from a biopsy are grown, then treated with commonly used chemotherapies to determine sensitivity or resistance. A report sent to the physician details which drugs or drug combinations were effective.

Market

While the market is for all solid tumors, we will begin by focusing on ovarian cancer .

Preliminary Results

Predictive Oncology conducted a study in collaboration with UPMC Magee-Women's Hospital demonstrated 92% accuracy in predicting whether a tumor sample would respond to a specific drug compound.

Our Board

Maurice van Tilburg
Chairman

Maurice van Tilburg is the former Director of the Dutch National Growth fund where he oversees the largest government investments in the area of innovation and technology. Mr. van Tilburg was formerly the CEO of Euronext Amsterdam.

David Weinstein
CEO & Director

While at Dawson James, Mr. Weinstein directly sourced over $300 million in investments for small-cap biotech and healthcare companies. He also spearheaded the merger of two healthcare companies in personalized cancer diagnostics and assisted in its uplisting on Nasdaq.

Douglas W. Calder
Director

Since 2015, Mr. Calder has served as president and a director of Vycellix, Inc and its subsidiaries and affiliates. He has also served as a member of the board of directors for Zevra Therapeutics, Inc. (NASDAQ: ZVRA) since April 2023; member of the board of directors for NextGenNK since June 2019; member of the board of directors of BioFlorida since January 2019, and a member of the Society for Natural Immunity since July 2018.

Mark A. Collins, PhD
Director

Dr. Collins has dedicated his 40-year career to leveraging computers in drug discovery, blending biology, AI, and software. He has played key roles in biotech startups, large Pharma, and tech companies, leading several to successful exits. Dr. Collins is currently the Chief Scientific Officer at UndauntedBio Inc., where he has served since 2022, a company that takes a unique AI-driven clinically informed, network-medicine approach to repurposing existing drugs for acute and chronic neuropathic pain conditions.

James A. McNulty
Director

Mr. McNulty serves as CFO for MIRALOGX, LLC, a privately held incubator which develops and licenses pharmaceutical intellectual property to private and public entities. Mr. McNulty is currently Interim CFO for Inhibitor Therapeutics, Inc. (OTCQB: INTI), where he has served since 2022. After leaving public accounting in 1998 after a 26-year career in Tampa as founder of three CPA firms, he served as CFO in the biopharmaceutical industry, including 3 years with Star Scientific (NASDAQ: STSI) and 15 years with BioDelivery Sciences International (NASDAQ: BDSI).

Renovaro's Dendritic Cell Cancer Vaccine

Nex-Gen DC therapeutic platform

RENOVARO
LIVE LONGER

Allogeneic CD34+ derived; gene modified dendritic cell therapy

- DCs loaded with patients' tumor lysate and can activate strong immune system against multiple tumor antigens
- Collaboration with renowned immunologist **Dr. Anahid Jewett (UCLA)**, manuscript submitted to Cell & Molecular Immunology (Nature, under review)

Advantages against existing autologous DC therapies [Ex. Dendreon PROVENGE®]

- Allogeneic off-the-shelf product with personalized antigen
- Multiple cancer antigen recognition. Highly potent. No immune suppression
- Quicker to manufacture. Short turnaround time to treat patients (Target to1 week)
- Gene-modification leads to enhanced antitumor activity. Multimodal immune activation
- Safe & Long-lasting therapeutic response
- Potential to combine with other therapeutic modalities



Further improvements with the help of RenovaroCube/AI

- Identify TAA/Neo Ag panels to transfer DCCV to a fully off-the-shelf treatment and as companion diagnostic
- CD34 donor screening for best yield and decreasing manufacturing failures
- Identify additional factors to enhance DCCV potency

DCCV Competitive Landscape

RENOVARO
LIVE LONGER

Renovaro DCCV platform: the only CD34+ derived gene-modified allogeneic dendritic cell therapy

Dendreon
- Autologus DCs
- Single PCP antigen. Pca
- **FDA Approved**. USA

Amphera
- Autologus DCs
- Peptide Ag. Pancreatic cancer
- USA

Coimmune
- Autologus DCs
- RCC-mRNA
- USA

JW CreaGene
- Autologus DCs
- CTP-conjugated TAA
- Liver/RCC
- KOREA

Jonsson Comprehensive Cancer Center & Merk
- Autologus DCs
- Lung/NSSLC/Meso
- USA

Indications



RenovaroBio
- Gene-modified, CD34+ derived DCCV
- Maximizes likelihood of clinical benefit with relevant pan-tumor Ag
- Maximizes treatment effect/potency with genetic enhancements

Northwest Biotherapeutics
- Autologus DCs
- Whole tumor lysate
- GBM
- USA

- **Mendus** (acquired DC Prime) (Sweden, public SV)
- Eng. cancer line to express DC markers, co-injected with alloDC
- EU

Aivita Biomedical
- Autologus DCs
- Whole tumor lysate
- GBM/Melanoma
- USA

Genzyme/Sanofi
- Allo DCs
- RCC
- USA

RENB DCCV Personalized Medicine

RENOVARO
LIVE LONGER



Indications:

- Pancreatic
- TNBC: Triple Negative Breast Cancer
- Prostate Cancer
- NSCLC

DCCV
Early Clinical Development Plan

Pre-IND communication with the FDA completed. Currently working towards submitting an IND

- ☑ Pre-clinical evaluation
- ☑ Pre-IND meeting with the FDA
- → In-process for IND-filing with the FDA

Clinical path: First-in-Human Open Label Ascending Dose Study in Multiple Solid Tumors

Phase I

- Up to 18 patients
- Pancreatic, TNBC, Prostate, NSCLC
- Indications with unmet need
- Characterize Safety of DCCV
- Evaluate and select dose level
- Identify early signs of efficacy

RMAT or other designation

Based on overall response

Pivotal Phase II

- Up to 40 patients (10/indication)
- Pancreatic, TNBC, Prostate, NSCLC
- Confirm efficacy data

BLA

Near Term Key Developments



Investment Summary

- **Long Term Goal:** Deliver a point of care solution for multi-cancer early detection from a simple blood draw - when cancer is detected to deliver a personalized cancer vaccine
- **Inflection Point in Medicine:**
  - 90% of cancers could be effectively treated if diagnosed in an early stage
  - Nvidia's latest chip sets make it possible to run the trillions of calculations needed for early cancer detection & personalized cancer vaccines
- **Innovative Technology:** Developing AI Cube platform, a cost-effective next generation of highly accurate diagnostics using a multi-omics, multi-modal AI-powered diagnostic engine for applying liquid biopsies
- **Product Pipeline: Two platforms synergistically working together**
  - AI/ML Cube for cancer diagnostics and therapy selection creates value streams from broad range of products and services
  - Gene infused allogenic DCCV in early clinical development plan
  - Searching for high frequency mutations in multiple solid tumors to generate the antigen panel and work as companion diagnostics
- **New Leadership:** Team of technology, biotechnology and pharmaceutical experts driving new focus and strategy

Capital Market Summary

RENB NASDAQ Listed	
Shares Outstanding	158.7M
Options/Warrants	12.6M
Sector	Healthcare
Industry	Biotechnology
Fiscal Year End	June 30

News Releases

- Renovaro Issues Shareholder Letter and Provides Corporate Update - Jan 7, 2025
- Renovaro Appoints Nathen Fuentes as Chief Financial Officer - Jan 7, 2025
- Renovaro to Acquire Predictive Oncology in All-Stock Transaction - Jan 6, 2024
- Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV - Dec 30, 2024
- RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program - Dec 23, 2024
- Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection - Dec 20, 2024
- Renovaro Issues Shareholder Letter and Provides Corporate Update - Nov 4, 2024
- RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing - Oct 17, 2024
- Renovaro Announces Strategic Restructuring and Leadership Transition - Oct 16, 2024

Upcoming & Past Events

- Molecular Analysis for Precision Oncology Congress – October 16, 2024
- European Society for Medical Oncology (ESMO) Congress – September 15, 2024

RENOVARO
LIVE LONGER

AI Driven Nx Generation Precision Oncology

NASDAQ: RENB

Investor Relations
Chris Tyson
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us

renovarogroup.com